Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedtaxol
Educational only, not medical advice. OncoForge makes no claim that Taxol treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Reported figures
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
0
Observational
1
Case report
0
Review
0
Preclinical
0
Other
0
1 studies1 human
Tracking 1 published study of Taxol: 1 in humans.
Reported direction across studies: 1 inconclusive.
These counts summarize what the studies reported; they are not a measure of whether Taxol works.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Jan 2008 · retrospective registry review
This retrospective study reviewed 22 women with ovarian carcinosarcoma treated at one institution. Most patients had advanced disease, and the authors reported median survival and progression-free intervals for different surgery and chemotherapy groups. Survival was not significantly different between the cisplatin/ifosfamide group and the carboplatin/taxol group. The study suggests these regimens were used in this rare cancer, but it does not establish which one is better.
Reported effects: median survival for the entire cohort 38 mo, n=22 · median survival for 18 optimally debulked (<1 cm) patients 46 mo, n=18 · +3 more
Twenty-two patients were identified, and all but two presented with advanced stage disease.
Median survival for the entire cohort was 38 months.
Median survival was 46 months for optimally debulked patients and 27 months for suboptimally debulked patients.
In the cisplatin and ifosfamide group, median progression-free interval was 13 months and median survival was 51 months.
In the carboplatin and taxol group, median progression-free interval was 6 months and median survival was 38 months.
The difference in survival between the two chemotherapy groups was not statistically significant (P=0.48).
Limitations: Retrospective single-institution review; Small sample size; No randomized control group; Non-comparative treatment groups with likely selection bias; Rare cancer with limited generalizability; Survival differences were not statistically significant.
This is an observational outcomes study in ovarian carcinosarcoma evaluating surgery and chemotherapy regimens.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
What changed recently
The latest additions to Taxol's evidence base, and anything that's been retracted.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
These are doses as studied or reported, never a recommendation. The right amount of Taxol depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies
Carcinosarcoma of the ovarycisplatin 40 mg/m(2) x 1 day and ifosfamide 1200 mg/m(2)/day x 4 days every 28 days; carboplatin AUC 5 and taxol 175 mg/m(2) every 21 days · Human · observational · Jan 2008
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.